# Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Source: https://onco.cc/trials/nct07397338/  
OnCo record `nct07397338` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Daraxonrasib, Elironrasib, Zoldonrasib in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.

## Summary

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT07397338 by Revolution Medicines, Inc., with 370 participants planned, started 2026-01-30 and due to reach its primary completion in 2029-05. Interventions recorded: Daraxonrasib, Elironrasib, Zoldonrasib, Ivonescimab, Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only). Conditions listed: Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07397338
- Phase: 1/2
- Setting: A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) Inhibitors in Combination With Ivonescimab With or Without Other Anti-Cancer Agents in Patients With Solid Tumors
- Sponsor: Revolution Medicines, Inc.
- Enrolled: 370

## Sources

- ClinicalTrials.gov NCT07397338: https://clinicaltrials.gov/study/NCT07397338

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/), [Elironrasib](https://onco.cc/drugs/elironrasib/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Zoldonrasib](https://onco.cc/drugs/zoldonrasib/)
- companies: [Revolution Medicines](https://onco.cc/companies/revolution-medicines/)

---
JSON: https://onco.cc/api/v1/entities/nct07397338.json